Page last updated: 2024-10-24

caffeine and Reperfusion Injury

caffeine has been researched along with Reperfusion Injury in 19 studies

Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.

Research Excerpts

ExcerptRelevanceReference
"One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle."7.73Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005)
"Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity."5.43Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016)
"Treatment with theanine (1 mg/kg body mass, intraperitoneal injection) alone significantly reduced cerebral infarction induced by cerebral ischemia-reperfusion, but caffeine (10 mg/kg, intravenous administration) alone only had a marginal effect."5.39Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats. ( Feng, Y; Gou, L; Ling, X; Liu, Y; Sun, L; Tian, X; Wang, L; Yin, X, 2013)
"Rosuvastatin increases extracellular adenosine formation, which provides protection against ischemia-reperfusion injury in humans in vivo."5.14Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. ( Boerman, OC; Dekker, D; Meijer, P; Oyen, WJ; Rongen, GA; Scheffer, GJ; Smits, P; van den Broek, PH; Wouters, CW, 2009)
"One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle."3.73Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005)
"Transient retinal ischemia is a major complication of retinal degenerative diseases and contributes to visual impairment and blindness."1.46Treatment with A ( Aires, ID; Ambrósio, AF; Baqi, Y; Boia, R; Cunha, RA; Elvas, F; Madeira, MH; Müller, CE; Rodrigues-Neves, AC; Santiago, AR; Szabó, EC; Tomé, ÂR; Tralhão, P, 2017)
"Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity."1.43Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016)
"Caffeine displays a broad array of actions on the brain."1.40Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury. ( Daglioglu, YK; Erdogan, S; Kilicdag, H; Zorludemir, S, 2014)
"Treatment with theanine (1 mg/kg body mass, intraperitoneal injection) alone significantly reduced cerebral infarction induced by cerebral ischemia-reperfusion, but caffeine (10 mg/kg, intravenous administration) alone only had a marginal effect."1.39Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats. ( Feng, Y; Gou, L; Ling, X; Liu, Y; Sun, L; Tian, X; Wang, L; Yin, X, 2013)
"Adenosine treatment after ischemia protected renal function and improved tubular histology."1.31Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation. ( Emala, CW; Lee, HT, 2001)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (26.32)18.2507
2000's7 (36.84)29.6817
2010's7 (36.84)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boia, R1
Elvas, F1
Madeira, MH1
Aires, ID1
Rodrigues-Neves, AC1
Tralhão, P1
Szabó, EC1
Baqi, Y1
Müller, CE1
Tomé, ÂR1
Cunha, RA1
Ambrósio, AF1
Santiago, AR1
Muhammad, M1
El-Ta'alu, AB1
Mohammed, MA1
Yarube, IU1
Nuhu, JM1
Yusuf, I1
Daneji, UA1
Sun, L1
Tian, X1
Gou, L1
Ling, X1
Wang, L1
Feng, Y1
Yin, X1
Liu, Y2
Kilicdag, H1
Daglioglu, YK1
Erdogan, S1
Zorludemir, S1
Chou, WC1
Kao, MC1
Yue, CT1
Tsai, PS1
Huang, CJ1
Puri, N1
Mohey, V1
Singh, M1
Kaur, T1
Pathak, D1
Buttar, HS1
Singh, AP1
Meijer, P1
Oyen, WJ3
Dekker, D1
van den Broek, PH2
Wouters, CW1
Boerman, OC3
Scheffer, GJ1
Smits, P3
Rongen, GA3
Saini-Chohan, HK1
Dhalla, NS1
Li, Q1
Jiao, J1
Zhang, C1
Lou, J1
Riksen, NP2
Ramakers, BP2
Engbersen, R1
Chen, L1
Lu, XY1
Li, J1
Fu, JD1
Zhou, ZN1
Yang, HT1
Zhou, Z1
Jaspers, R1
Brouwer, RM1
Steinmetz, N1
Yeung, HM1
Kravtsov, GM1
Ng, KM1
Wong, TM1
Fung, ML1
Morton, JW1
Duncan, CJ1
Phillis, JW1
Gao, H1
Korthuis, RJ1
Benoit, JN1
Li, B1
Rosenbaum, PS1
Jennings, NM1
Maxwell, KM1
Roth, S1
Schreieck, J1
Richardt, G1
Lee, HT1
Emala, CW1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial[NCT00315510]Phase 220 participants Interventional2006-04-30Completed
Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00457652]Phase 424 participants (Actual)Interventional2007-06-30Completed
Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.[NCT00554138]24 participants (Actual)Interventional2007-11-30Completed
Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury[NCT00987974]Phase 448 participants (Anticipated)Interventional2009-09-30Completed
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?[NCT00457405]Phase 410 participants (Actual)Interventional2007-06-30Completed
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00430170]Phase 420 participants (Actual)Interventional2007-01-31Completed
Caffeine Reduces Acute Ischemic Preconditioning[NCT00184912]24 participants Interventional2003-09-30Completed
The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)[NCT02118753]24 participants (Actual)Interventional2014-03-31Completed
The Effect of Aminophylline on Preventing Acute Kidney Injury in Pediatric Patients Undergoing Open Heart Surgery[NCT03897335]Phase 380 participants (Anticipated)Interventional2019-02-07Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for caffeine and Reperfusion Injury

ArticleYear
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:6

    Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru

2009
Caffeine prevents protection in two human models of ischemic preconditioning.
    Journal of the American College of Cardiology, 2006, Aug-15, Volume: 48, Issue:4

    Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi

2006
Caffeine prevents protection in two human models of ischemic preconditioning.
    Journal of the American College of Cardiology, 2006, Aug-15, Volume: 48, Issue:4

    Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi

2006
Caffeine prevents protection in two human models of ischemic preconditioning.
    Journal of the American College of Cardiology, 2006, Aug-15, Volume: 48, Issue:4

    Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi

2006
Caffeine prevents protection in two human models of ischemic preconditioning.
    Journal of the American College of Cardiology, 2006, Aug-15, Volume: 48, Issue:4

    Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi

2006

Other Studies

17 other studies available for caffeine and Reperfusion Injury

ArticleYear
Treatment with A
    Cell death & disease, 2017, 10-05, Volume: 8, Issue:10

    Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Humans; Inflammation; Ischemia; Mal

2017
Effect of Caffeine on Serum Tumour Necrosis Factor Alpha and Lactate Dehydrogenase in Wistar Rats Exposed to Cerebral Ischaemia-reperfusion Injury.
    Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria, 2018, Jun-30, Volume: 33, Issue:1

    Topics: Animals; Caffeine; Disease Models, Animal; Inflammation; L-Lactate Dehydrogenase; Liver; Male; Rats,

2018
Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats.
    Canadian journal of physiology and pharmacology, 2013, Volume: 91, Issue:7

    Topics: Animals; Antioxidants; Brain Edema; Brain Ischemia; Caffeine; Cerebral Cortex; Cerebral Infarction;

2013
Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2014, Volume: 27, Issue:14

    Topics: Animals; Animals, Newborn; Apoptosis; Brain; Caffeine; Disease Models, Animal; Female; Hypoxia-Ische

2014
Caffeine Mitigates Lung Inflammation Induced by Ischemia-Reperfusion of Lower Limbs in Rats.
    Mediators of inflammation, 2015, Volume: 2015

    Topics: Animals; Caffeine; Lower Extremity; Lung; Male; Oxidative Stress; Peroxidase; Pneumonia; Rats; Rats,

2015
Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:4

    Topics: Acute Kidney Injury; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2

2016
Attenuation of ischemia-reperfusion-induced alterations in intracellular Ca2+ in cardiomyocytes from hearts treated with N-acetylcysteine and N-mercaptopropionylglycine.
    Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:12

    Topics: Acetylcysteine; Animals; Caffeine; Calcium; Cardiotonic Agents; Cell Survival; Dose-Response Relatio

2009
Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.
    Drug development and industrial pharmacy, 2014, Volume: 40, Issue:2

    Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactio

2014
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration

2005
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration

2005
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration

2005
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:1

    Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration

2005
Intermittent hypoxia protects cardiomyocytes against ischemia-reperfusion injury-induced alterations in Ca2+ homeostasis and contraction via the sarcoplasmic reticulum and Na+/Ca2+ exchange mechanisms.
    American journal of physiology. Cell physiology, 2006, Volume: 290, Issue:4

    Topics: Altitude; Animals; Caffeine; Calcium; Calcium-Transporting ATPases; Homeostasis; Hypoxia; Male; Musc

2006
Chronic intermittent hypoxia alters Ca2+ handling in rat cardiomyocytes by augmented Na+/Ca2+ exchange and ryanodine receptor activities in ischemia-reperfusion.
    American journal of physiology. Cell physiology, 2007, Volume: 292, Issue:6

    Topics: Animals; Body Weight; Caffeine; Calcium; Electrophysiology; Gene Expression Regulation; Heart; Heart

2007
Effect of osmotic pressure on cellular damage in the perfused rat kidney.
    Biochemical Society transactions, 1994, Volume: 22, Issue:4

    Topics: Animals; Caffeine; Calcium; In Vitro Techniques; Kidney; L-Lactate Dehydrogenase; Mannitol; Osmotic

1994
The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil.
    Brain research, 1995, Dec-24, Volume: 705, Issue:1-2

    Topics: Animals; Behavior, Animal; Caffeine; Carotid Arteries; Cerebral Cortex; Cerebrovascular Disorders; D

1995
Effects of hypoxia/reoxygenation on aortic vasoconstrictor responsiveness.
    Free radical biology & medicine, 1996, Volume: 21, Issue:5

    Topics: Animals; Aorta, Thoracic; Caffeine; Catalase; Endothelium, Vascular; Enzyme Inhibitors; Free Radical

1996
Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat.
    Experimental eye research, 1999, Volume: 68, Issue:1

    Topics: Animals; Caffeine; Electroretinography; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawl

1999
Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart.
    Journal of molecular and cellular cardiology, 1999, Volume: 31, Issue:1

    Topics: Adenine; Adenosine; Aminoimidazole Carboxamide; Animals; Caffeine; Creatine Kinase; Electrocardiogra

1999
Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:3

    Topics: Adenosine; Analysis of Variance; Animals; Bucladesine; Caffeine; Kidney; Male; Purinergic P1 Recepto

2001